These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33352665)

  • 1. Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with
    Tashiro T; Imamura K; Tomita Y; Tamanoi D; Takaki A; Sugahara K; Sato R; Saruwatari K; Sakata S; Inaba M; Ushijima S; Hirata N; Sakagami T
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
    Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
    Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel
    Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T
    Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.
    Lim CA; Banyi N; Tucker T; Ionescu DN; Melosky B
    Curr Oncol; 2022 Feb; 29(2):848-852. PubMed ID: 35200571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.
    Wang S; Wu X; Zhao J; Chen H; Zhang Z; Wang M; Xu C; Wang Y; Wang L; He Z; Wang Q
    Clin Lung Cancer; 2021 May; 22(3):e366-e370. PubMed ID: 32651063
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
    Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
    Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
    Kim SJ; Kim S; Kim DW; Kim M; Keam B; Kim TM; Lee Y; Koh J; Jeon YK; Heo DS
    Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
    Wang W; Sun X; Hui Z
    Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
    Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
    Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
    Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
    Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
    [No Abstract]   [Full Text] [Related]  

  • 12. EGFR mutation genotyping and ALK status determination in liquid-based cytology samples of non-small cell lung cancer.
    Satoh Y; Matsuo Y; Kuba T; Yamashita K; Sawano M; Tozaka S; Yamazaki H; Sonoda D; Mikubo M; Naito M; Matsui Y; Shiomi K; Yoshida T; Murakumo Y
    Virchows Arch; 2020 May; 476(5):753-762. PubMed ID: 31823000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
    Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
    Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaplastic lymphoma kinase expression in small-cell lung cancer.
    Kondoh C; Horio Y; Hayashi Y; Ebi H; Hida T; Hasegawa Y; Yatabe Y
    Histopathology; 2019 Jul; 75(1):20-28. PubMed ID: 30790327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
    Caumont C; Veillon R; Gros A; Laharanne E; Bégueret H; Merlio JP
    Lung Cancer; 2016 Feb; 92():15-8. PubMed ID: 26775590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.
    Kim HS; Lee JH; Nam SJ; Ock CY; Moon JW; Yoo CW; Lee GK; Han JY
    J Thorac Oncol; 2018 May; 13(5):636-648. PubMed ID: 29378266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alectinib and mixed large cell neuroendocrine carcinoma of the lung.].
    Hegedűs F; Sükösd F; Tiszlavicz L; Furák J; Pálföldi R; Fejes Z; Zombori T
    Orv Hetil; 2023 Apr; 164(14):548-554. PubMed ID: 37031440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples.
    Abe H; Kawahara A; Azuma K; Taira T; Takase Y; Fukumitsu C; Murata K; Yamaguchi T; Akiba J; Ishii H; Okamoto I; Hoshino T; Takamori S; Kage M
    J Thorac Oncol; 2015 May; 10(5):800-805. PubMed ID: 25898958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.